XOC PHARMACEUTICALS INC has a total of 38 patent applications. It increased the IP activity by 83.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are NIKEM RESEARCH SRL, EPIX DELAWARE INC and KUEHNERT SVEN.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | Australia | 4 | |
#3 | Brazil | 3 | |
#4 | Canada | 3 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | Israel | 3 | |
#7 | WIPO (World Intellectual Property Organization) | 3 | |
#8 | China | 2 | |
#9 | Mexico | 2 | |
#10 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Borland Scott | 31 |
#2 | Armer Thomas | 31 |
#3 | Guzman Miguel | 31 |
#4 | Mckinley Geoff | 23 |
#5 | Gerencser Janos | 9 |
#6 | Szabolcs Armin | 9 |
#7 | Szabolcs Ármin | 6 |
#8 | Gerencser János | 6 |
#9 | Scott Borland | 4 |
#10 | Miguel Guzman | 4 |
Publication | Filing date | Title |
---|---|---|
AU2018275873A1 | Ergoline derivatives for use in medicine | |
WO2016118540A1 | Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis | |
AU2016209490A1 | Isoergoline compounds and uses thereof | |
AU2016209492A1 | Ergoline compounds and uses thereof |